{"entity":{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","aka":[],"tldr":"Led CheckMate 017, the first trial to show immunotherapy beats chemotherapy in lung cancer.","summary":"Julie R. Brahmer is Director of Thoracic Oncology and Co-Director of the Upper Aerodigestive Department at the Bloomberg~Kimmel Institute, Johns Hopkins Hospital and Sidney Kimmel Comprehensive Cancer Center. She is a thoracic oncologist known for leading CheckMate 017, the first trial to show immunotherapy beats chemotherapy in lung cancer, alongside early PD-L1 antibody work. Her selected paper reports nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. She is also a long-term follow-up author of the first-line pembrolizumab trials and works on mesothelioma.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Julie_Brahmer","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/julie-brahmer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brahmer%20JR%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","mesothelioma"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":["nivolumab","pembrolizumab"],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Thoracic Oncology; Co-Director, Upper Aerodigestive Department, Bloomberg~Kimmel Institute","institutionId":"johns-hopkins","specialisms":["Lung cancer immunotherapy","PD-1/PD-L1","Mesothelioma"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/julie-brahmer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brahmer%20JR%5BAuthor%5D"}],"papers":[{"title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1504627","doi":"10.1056/NEJMoa1504627"},{"title":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2202170","doi":"10.1056/NEJMoa2202170"},{"title":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1200690","doi":"10.1056/NEJMoa1200690"}]},"route":"/people/julie-brahmer/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"}],"paper":[{"id":"paper-checkmate-017-nejm-2015","kind":"paper","name":"CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy","route":"/key-papers/paper-checkmate-017-nejm-2015/"},{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/"},{"id":"paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006","kind":"paper","name":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","route":"/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/"},{"id":"paper-topalian-anti-pd1-nejm-2012","kind":"paper","name":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","route":"/key-papers/paper-topalian-anti-pd1-nejm-2012/"}]}}